Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Venture&Growth
Sanifit
Spanish Therapeutics company developing treatment of vascular calcification disorders of kidney patients.
Venture&Growth
Proverum
Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin, developing novel treatment solutions for patients with symptomatic benign prostatic hyperplasia (BPH). BPH is a highly prevalent condition impacting an estimated 14 million
Venture&Growth
Tagworks
Tagworks Pharmaceuticals is a privately held therapeutics company based in the Netherlands. It leverages unique technologies to increase efficacy and decrease toxicity across multiple systemic treatment modalities. The company has pioneered a unique and proprietary Click-to-Release drug development technology, enabling
